As global markets navigate a landscape marked by economic uncertainties and fluctuating investor sentiment, Asian markets have shown resilience with some indices reaching multi-year highs, particularly in China where easing trade tensions have bolstered risk appetite. In this environment, identifying undervalued stocks becomes crucial as investors seek opportunities that may be trading below their intrinsic value, offering potential for growth despite broader market challenges.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Zhejiang Century Huatong GroupLtd (SZSE:002602) | CN¥18.51 | CN¥36.85 | 49.8% |
| Yonghui Superstores (SHSE:601933) | CN¥4.61 | CN¥9.13 | 49.5% |
| Wuhan Guide Infrared (SZSE:002414) | CN¥12.78 | CN¥25.25 | 49.4% |
| Tibet Tianlu (SHSE:600326) | CN¥12.14 | CN¥24.19 | 49.8% |
| TESEC (TSE:6337) | ¥2080.00 | ¥4137.61 | 49.7% |
| Mobvista (SEHK:1860) | HK$19.19 | HK$37.72 | 49.1% |
| LianChuang Electronic TechnologyLtd (SZSE:002036) | CN¥9.97 | CN¥19.91 | 49.9% |
| IbidenLtd (TSE:4062) | ¥13705.00 | ¥27290.25 | 49.8% |
| East Buy Holding (SEHK:1797) | HK$20.26 | HK$39.94 | 49.3% |
| Andes Technology (TWSE:6533) | NT$256.00 | NT$507.58 | 49.6% |
Here we highlight a subset of our preferred stocks from the screener.
Tongguan Gold Group (SEHK:340)
Overview: Tongguan Gold Group Limited is an investment holding company involved in the exploration, mining, processing, smelting, and sale of gold and related products in China with a market cap of HK$12.27 billion.
Operations: The company generates revenue primarily from its gold mining operations, amounting to HK$1.69 billion.
Estimated Discount To Fair Value: 45.5%
Tongguan Gold Group's earnings have surged, growing by 256.7% over the past year, with future earnings expected to grow significantly at 33.3% annually, outpacing the Hong Kong market. The stock is trading at HK$2.79, well below its estimated fair value of HK$5.12, suggesting it is highly undervalued based on discounted cash flow analysis. Despite a volatile share price recently, its revenue growth remains robust and above market averages in Hong Kong.
- Our comprehensive growth report raises the possibility that Tongguan Gold Group is poised for substantial financial growth.
- Navigate through the intricacies of Tongguan Gold Group with our comprehensive financial health report here.
Xi'an International Medical Investment (SZSE:000516)
Overview: Xi'an International Medical Investment Company Limited provides healthcare services and has a market cap of CN¥11.22 billion.
Operations: Xi'an International Medical Investment Company Limited's revenue segments include healthcare services.
Estimated Discount To Fair Value: 46.6%
Xi'an International Medical Investment is trading at CN¥5.01, significantly below its estimated fair value of CN¥9.38, highlighting potential undervaluation based on discounted cash flow analysis. Despite recent financial challenges with declining sales and a net loss of CNY 293.66 million for the nine months ending September 2025, earnings are projected to grow robustly at 88.34% annually, with profitability expected within three years—outpacing average market growth in China.
- Insights from our recent growth report point to a promising forecast for Xi'an International Medical Investment's business outlook.
- Click here and access our complete balance sheet health report to understand the dynamics of Xi'an International Medical Investment.
Nan Juen International (TPEX:6584)
Overview: Nan Juen International Co., Ltd. operates in the research, development, manufacturing, and trading of steel ball guide rails across various regions including the United States, Asia, Europe, and Africa with a market capitalization of NT$20.24 billion.
Operations: The company's revenue is primarily derived from the manufacture and sale of steel ball rails, amounting to NT$2.12 billion.
Estimated Discount To Fair Value: 32.8%
Nan Juen International, trading at NT$307, is significantly undervalued compared to its estimated fair value of NT$456.7 based on discounted cash flow analysis. Despite a highly volatile share price and debt not well covered by operating cash flow, the company shows strong potential with earnings forecasted to grow at 64.8% annually—far outpacing the Taiwan market's average growth rate. Revenue is also expected to increase significantly, supporting long-term profitability prospects.
- Our earnings growth report unveils the potential for significant increases in Nan Juen International's future results.
- Get an in-depth perspective on Nan Juen International's balance sheet by reading our health report here.
Turning Ideas Into Actions
- Access the full spectrum of 272 Undervalued Asian Stocks Based On Cash Flows by clicking on this link.
- Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
- Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Curious About Other Options?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Xi'an International Medical Investment might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com